Data / Form D filings / OS Therapies Inc
OS Therapies Inc: Form D filings
OS Therapies Inc, a biotechnology company in Grasonville, MD, filed 13 Form D notices with the SEC between 2019 and 2026. The latest, on October 23, 2026, reports $7.2 million sold of a $12.3 million offering to 9 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 115 Pullman Crossing Road Suite 103, Grasonville, MD, 21638
- Phone
- (410) 297-7793
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1795091
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Oct 23, 2026 | New notice | $12,282,478 | $7,172,429 | $5,110,049 | 9 | Oct 15, 2026 | sec.gov |
| Aug 25, 2026 | New notice | $10,000,000 | $5,000,000 | $5,000,000 | 10 | Aug 10, 2026 | sec.gov |
| Jul 16, 2026 | New notice | $9,250,000 | $1,600,000 | $7,650,000 | 1 | Jun 30, 2026 | sec.gov |
| Mar 6, 2026 | New notice | $2,000,000 | $2,000,000 | 9 | Mar 4, 2026 | sec.gov | |
| Jan 20, 2026 | New notice | $7,531,884 | $3,498,650 | $4,033,234 | 9 | Jan 14, 2026 | sec.gov |
| Sep 10, 2025 | New notice | $3,777,808 | $3,777,808 | 10 | Sep 2, 2025 | sec.gov | |
| Jul 16, 2025 | New notice | $4,216,794 | $4,216,794 | 27 | Jun 23, 2025 | sec.gov | |
| Jan 22, 2025 | New notice | $10,000,000 | $7,103,000 | $2,897,000 | 34 | Dec 31, 2024 | sec.gov |
| Dec 14, 2023 | New notice | $2,000,000 | $700,000 | $1,300,000 | 3 | Dec 8, 2023 | sec.gov |
| Jan 11, 2023 | New notice | $2,000,000 | $2,000,000 | 11 | Nov 16, 2022 | sec.gov | |
| Sep 1, 2021 | New notice | $5,000,000 | $1,000,000 | $4,000,000 | 1 | Jul 15, 2021 | sec.gov |
| May 1, 2020 | New notice | $5,000,000 | $0 | $5,000,000 | 0 | Yet to occur | sec.gov |
| Dec 5, 2019 | New notice | $500,000 | $359,000 | $141,000 | 11 | Jul 25, 2018 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Paul A. Romness | Executive Officer, Director | Chairman, President and Chief Executive Officer |
| Robert G. Petit | Executive Officer | Chief Medical Officer and Chief Scientific Officer |
| Francis Knuettel II | Executive Officer | Chief Financial Officer |
| John Ciccio | Director | |
| Avril McKean Dieser | Director | |
| Craig Eagle | Director | |
| Olivier Jarry | Director | |
| Theodore F. Search | Director | |
| Kerry Clem | Executive Officer | Chief Commercial Officer |
Other biotechnology companies in Maryland that filed recently
- Accufy Diagnostics, Inc. $2 million · Oct 28, 2026
- Kaigene, Inc. $55 million · Oct 14, 2026
- Templar Nova, Inc. $7 million · Oct 7, 2026
- Monocacy Therapeutics Inc. $25,000 · Oct 7, 2026
- Seraxis Holdings, Inc. $10 million · Sep 24, 2026
- Uvantis Therapeutics, Inc. $100,000 · Sep 23, 2026
Every Form D from the week of Oct 19, 2026 · All recent filings in Maryland · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what OS Therapies Inc reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.